CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for GB Sciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

GB Sciences Inc
6450 Cameron St Ste 110A
Phone: (888) 895-3594p:888 895-3594 LAS VEGAS, NV  89118-4337  United States Ticker: GBLXGBLX
Business Summary
GB Sciences, Inc. is a biopharmaceutical research and development company. The Company develops disease-targeted formulations of cannabis and other plant-inspired therapeutic mixtures for the prescription drug market through its wholly owned subsidiary, GbS Global Biopharma, Inc. (GBSGB). The Company's primary focus is on preparing its lead program for the treatment of the motor symptoms of Parkinson's disease (PD) in a human clinical trial. Through GBSGB, the Company is engaged in the research and development of plant-inspired medicines, with virtual operations in North America and Europe. GBSGB has a portfolio of intellectual property containing both plant-inspired formulations and its artificial intelligence (AI)-enabled drug discovery platform, as well as research contracts and various supplier arrangements. GBSGBs intellectual property covers a range of over 65 medical conditions, from which five drug development programs are in the preclinical stage of drug development.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20233/31/2023YesYes--Yes

Industries
SIC Code Description
1311 Crude petroleum and natural gas
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer, Interim Chief Financial Officer JohnPoss 75 4/14/2023 7/27/2015
President, Chief Science Officer, Director AndreaSmall-Howard 54 6/16/2021 6/16/2014
Chief Financial Officer, Treasurer ZachSwarts 35 6/9/2021 9/5/2019
Company Secretary Gary R.Henrie 69 6/8/2021 6/8/2021

Subsidiaries
Business Name Address City State/Province Country
GB SCIENCES LOUISIANA LLC 18350 PETROLEUM DR BATON ROUGE LA

Business Names
Business Name
Diabetic Treatment Centers of America,
ECRX, Inc.
FLAGSTICK VENTURES INC
6 additional Business Names available in full report.

General Information
Number of Employees: 3 (As of 3/31/2023)
Outstanding Shares: 406,071,028 (As of 2/12/2024)
Shareholders: 201
Stock Exchange: OTC
Federal Tax Id: 593733133
Email Address: info@gbsciences.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024